While other cancers have seen great improvements in outcomes
due to new therapies and treatment paradigms over the last decades, advanced
bladder cancer has been one of the few solid tumors for which no new major
breakthrough have been seen in thirty years.
However, all that changed a few weeks ago with the US Food
and Drug Administration (FDA) accelerated approval of atezolizumab (Tecentriq, Genentech, Inc), for the
treatment of advanced urothelial carcinoma, the most common type of bladder
cancer.
Atezolizumab is a targeted immunotherapy that acts as a
programmed cell death ligand inhibitor (PD-L1), and is the third agent approved
in cancer that targets the PD-1/PD-L1, PD-L2 checkpoint pathway (with nivolumab
and pembrolizumab being the other two).
No comments:
Post a Comment